<DOC>
	<DOCNO>NCT00592527</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate blood glucose achieve insulin detemir add-on current oral antidiabetic drug ( OAD ) treatment subject type 2 diabetes .</brief_summary>
	<brief_title>Safety Efficacy Insulin Detemir Combination With OADs Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 2 diabetes least 12 month since diagnosis Insulin naive subject OAD treatment least 4 month max . two OAD treatment Body mass index 30.0 kg/m2 HbA1c 7.011.0 % OAD treatment three OADs Secondary diabetes Known hypoglycaemia unawareness recurrent major hypoglycaemia judge Investigator Uncontrolled hypertension Known suspect allergy trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>